<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1836">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03611439</url>
  </required_header>
  <id_info>
    <org_study_id>Genescient</org_study_id>
    <nct_id>NCT03611439</nct_id>
  </id_info>
  <brief_title>Effects of an 8 Component Botanical Supplement on Mild and Moderate Alzheimer's Patients</brief_title>
  <official_title>Effects of an 8 Component Botanical Supplement on Mild and Moderate Alzheimer's Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genescient Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genescient Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This placebo-controlled, double blind study evaluates the treatment effects of adding a&#xD;
      multi-pathway botanical dietary supplement (ReBuilder) to the standard treatment regimens of&#xD;
      subjects diagnosed with mild or moderate stage Alzheimer's Disease. The objective of the&#xD;
      study is to determine if mild and moderate AD patients exhibit improved or stabilized&#xD;
      cognitive function when this supplement is added to maximum tolerated doses of their standard&#xD;
      treatments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, there is no treatment that can stop the progression of Alzheimer's Disease. The&#xD;
      investigators in this study have used transgenic Drosophila melanogaster models and machine&#xD;
      learning to develop an eight component botanical mixture (Geneaire™* ReBuilder™) that targets&#xD;
      multiple genetic pathways involved in brain aging and dementia that are homologous between&#xD;
      Drosophila and humans.&#xD;
&#xD;
      While beta-amyloid plaques and phosphorylated-tau tangles are diagnostic for AD, the cause(s)&#xD;
      of their soluble precursors that kill neurons has not been determined. The majority of AD&#xD;
      patients are diagnosed after 60 years of age. Many studies point to aging related processes&#xD;
      like inflammation, neural vascular damage, neural stress, altered cell metabolism,&#xD;
      inefficient cellular autophagy, microglial dysfunction, mitochondrial dysfunction, and poor&#xD;
      diet as potential causal factors in the decline of brain function over the decades that&#xD;
      precede an actual AD diagnosis. AD is a multifaceted pathology involving many biochemical&#xD;
      pathways and thus a multifaceted therapeutic approach may prove beneficial.&#xD;
&#xD;
      The goal of this study was to test ReBuilder on human cognitive function. During the 12-month&#xD;
      pilot study, the subjects were evaluated quarterly on the Mini Mental State Exam (MMSE),&#xD;
      Alzheimer's Disease Cooperative Study's Activities of Daily Living (ADCS-ADL), and the&#xD;
      Clinical Dementia Rating Sum of Boxes (CDR-SB).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2013</start_date>
  <completion_date type="Actual">December 25, 2015</completion_date>
  <primary_completion_date type="Actual">December 25, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, placebo-controlled, double blind study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>randomized, double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline Mini Mental State Exam (MMSE) Scores</measure>
    <time_frame>Change from baseline MMSE at 12 months</time_frame>
    <description>dementia questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Scores</measure>
    <time_frame>Change from baseline ADCS-ADL at 12 months</time_frame>
    <description>daily living activity questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline Clinical Dementia Rating Sum of Boxes (CDR-SB) Scores</measure>
    <time_frame>Change from baseline CDR-SB at 12 months</time_frame>
    <description>dementia assessment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Alzheimer Dementia</condition>
  <arm_group>
    <arm_group_label>ReBuilder Actives</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects take one 650 mg capsule by mouth twice a day for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ReBuilder Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects take one placebo capsule by mouth twice a day for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ReBuilder</intervention_name>
    <description>8-component botanical dietary supplement</description>
    <arm_group_label>ReBuilder Actives</arm_group_label>
    <other_name>MX100A</other_name>
    <other_name>Memex+</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive Placebo Capsule</description>
    <arm_group_label>ReBuilder Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed mild or moderate Alzheimer's Disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of heart disease&#xD;
&#xD;
          -  History of heart attack&#xD;
&#xD;
          -  History of cancer&#xD;
&#xD;
          -  History of stroke or transient ischemic attack&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 17, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2018</study_first_posted>
  <last_update_submitted>July 26, 2018</last_update_submitted>
  <last_update_submitted_qc>July 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

